3.94 USD
↘ 0.14 (3.50%)LIVE (AS OF 01:01 PM EDT)
Ernexa Therapeutics Inc. Common Stock
ERNANASDAQ • USD
Market: OPEN
Ernexa Therapeutics Inc. Common Stock (ERNA) is currently trading at $3.94. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest ERNA is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Sep 15, 2026.
Open?$4.01
High?$4.45
Low?$3.90
Prev. Close?$4.08
Volume?15.2K
Avg. Volume?52.9K
VWAP?$4.01
Rel. Volume?0.29x
Bid / Ask
Bid?$3.35 × 100
Ask?$4.56 × 100
Spread?$1.21
Midpoint?$3.96
Valuation & Ratios
Market Cap?4.8M
Shares Out?1.6M
Float?966.7K
Float %?59.2%
P/E Ratio?N/A
P/B Ratio?1.49
EPS?-$10.52
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Themes
Address
1035 CAMBRIDGE STREET
CAMBRIDGE, MA 02141
Phone: (617) 798-6700
CAMBRIDGE, MA 02141
Phone: (617) 798-6700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?80
Piotroski F-Score?0/9Weak
Altman Z-Score?-62.29Distress
Confidence?43%Low
Short InterestLow
Short % of Float?2.05%Low
Short Interest?19.8K
Days to Cover?1.0
Free Float966.7K
Avg Daily Volume36.1K
Settlement Date2026-08-31
Financial Health
Current Ratio?2.01Strong
Quick Ratio?2.01Strong
Cash Ratio?1.71Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.49CHEAP▾
Peers100
S&P87
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.0CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-383.5%WEAK▾
S&P3
ROA?-194.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-8878000
Enterprise Value?$-269361
Fundamentals ratios updated end of day